The discovery of a pathogenic BRCA2 mutation enabled the consideration of PARP inhibitor‐based combination therapy, emphasizing the critical role of molecular diagnostics in guiding individualized treatment for rare prostate cancer subtypes. This evidence concerns the gene BRCA2 and prostate cancer.